B7-H4 antibody data presented at ESMO 2017
SOUTH SAN FRANCISCO, Calif.—Biotechnology company Five Prime Therapeutics Inc. presented an oral poster discussion recently at the European Society for Medical Oncology (ESMO) 2017 Congress on FPA150, its novel B7-H4 therapeutic antibody. Five Prime is currently developing the monoclonal antibody, which has shown potent antibody-dependent cell-mediated cytotoxicity and T cell checkpoint blockade activity in vitro and notable dose-dependent antitumor efficacy in vivo.
“B7-H4 represents an ideal target for a therapeutic antibody,” said Dr. Bryan Irving, senior vice president of research at Five Prime. “B7-H4 is expressed in several solid tumor types not typically associated with PD-L1 expression and its expression negatively correlates with patient outcome. Moreover, B7-H4 represents a T cell checkpoint ligand that is not currently targeted by other immuno-oncology agents.”